These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1974725

  • 1. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT, Seidlin M, Hochster H, Laverty M.
    Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, McCaffrey RP, Liebman HA.
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [Abstract] [Full Text] [Related]

  • 4. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
    Dolin R, Lambert JS, Morse GD, Reichman RC, Plank CS, Reid J, Knupp C, McLaren C, Pettinelli C.
    Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 6. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA.
    N Engl J Med; 1990 May 10; 322(19):1340-5. PubMed ID: 2139174
    [Abstract] [Full Text] [Related]

  • 7. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC, Martin ES.
    Ann Pharmacother; 1992 Nov 10; 26(11):1347-51. PubMed ID: 1362093
    [Abstract] [Full Text] [Related]

  • 8. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
    Rozencweig M, McLaren C, Beltangady M, Ritter J, Canetta R, Schacter L, Kelley S, Nicaise C, Smaldone L, Dunkle L.
    Rev Infect Dis; 1990 Nov 10; 12 Suppl 5():S570-5. PubMed ID: 2166965
    [Abstract] [Full Text] [Related]

  • 9. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT.
    N Engl J Med; 1990 May 10; 322(19):1333-40. PubMed ID: 2139173
    [Abstract] [Full Text] [Related]

  • 10. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.
    Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F.
    J Acquir Immune Defic Syndr (1988); 1992 May 10; 5(1):60-4. PubMed ID: 1346633
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
    Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S.
    Lancet; 1990 Sep 01; 336(8714):526-9. PubMed ID: 1975038
    [Abstract] [Full Text] [Related]

  • 15. Didanosine.
    Shelton MJ, O'Donnell AM, Morse GD.
    Ann Pharmacother; 1992 May 01; 26(5):660-70. PubMed ID: 1350471
    [Abstract] [Full Text] [Related]

  • 16. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS, Seidlin M, Valentine FT, Reichman RC, Dolin R.
    Clin Infect Dis; 1993 Feb 01; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
    Reddy MM, McKinley GF, Grieco MH.
    J Clin Lab Anal; 1991 Feb 01; 5(6):396-8. PubMed ID: 1774603
    [Abstract] [Full Text] [Related]

  • 18. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul 01; 12(3):249-58. PubMed ID: 8673528
    [Abstract] [Full Text] [Related]

  • 19. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
    Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischl M, Schooley R, Hirsch M, Soo W, Pettinelli C.
    Ann Intern Med; 1989 Feb 01; 110(3):189-94. PubMed ID: 2536257
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.